Benitec Biopharma Inc. (BNTC) Financial Analysis & Valuation | Quarter Chart
Benitec Biopharma Inc. (BNTC)
BNTCPrice: $11.99
Fair Value: 🔒
🔒score
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based ... more
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of nov... more
Description
Shares
| Market Cap | $314.70M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jerel A. Banks |
| IPO Date | 2014-06-24 | CAGR | — |
| Employees | 16 | Website | benitec.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BNTC chart loading...
Fundamentals
Technicals
| Enterprise Value | $458.17M | P/E Ratio | -11 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 194.66 | P/B Ratio | 1.81 |
| P/CF Ratio | -7.65 | P/FCF Ratio | -4.83 |
| EPS | $-1.09 | EPS Growth 1Y | -53.91% |
| EPS Growth 3Y | -93.4% | EPS Growth 5Y | -98.47% |
| Revenue Growth 1Y | 9166.67% | Gross Margin | 0.16% |
| Operating Margin | -82.33% | Profit Margin | -75.22% |
| ROE | -0.46% | ROA | -0.44% |
| ROCE | -0.49% | Current Ratio | 46.95 |
| Quick Ratio | 46.95 | Cash Ratio | 46.66 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 73.88 | Piotroski Score | 3 |